Showing results (71-80 of 123) with videos related to

Sort By:
Pageof 13
BMC Cancer|February 13, 2020
A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancerYoshihiro Hattori, Yuko Kono, Shoichi Itoh, et al.
Immunotherapy|May 25, 2021
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcomaHayato Kawachi, Kei Kunimasa, Yoji Kukita, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2020
Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patientKei Kunimasa, Yosuke Hirotsu, Yoshihiro Miyashita, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2020
Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA TrialMakoto Nishio, Tatsuya Yoshida, Toru Kumagai, et al.
Cancer Medicine|March 11, 2022
Comparison of sampling methods for next generation sequencing for patients with lung cancerKei Kunimasa, Shingo Matsumoto, Kazumi Nishino, et al.
Cancer Genetics|April 26, 2021
Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinibKei Kunimasa, Kazumi Nishino, Yoji Kukita, et al.
JACC. Cardiooncology|August 16, 2021
Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With OsimertinibKei Kunimasa, Risa Kamada, Toru Oka, et al.
Thoracic Cancer|February 24, 2018
HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1Toru Kumagai, Yasuhiko Tomita, Shin-Ichi Nakatsuka, et al.
Anticancer Research|September 6, 2017
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung CancerAkihiro Tamiya, Motohiro Tamiya, Kenji Nakahama, et al.
Molecular and Clinical Oncology|March 8, 2021
Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective studyYukio Kadokawa, Mari Takagi, Tomoe Yoshida, et al.
Pageof 13